<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Effects of stanozolol on normal and IL-1β-stimulated equine chondrocytes in vitro</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Mariana</forename><surname>Castro Martins</surname></persName>
							<idno type="ORCID">0000-0001-6028-4154</idno>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Equine Clinical Studies</orgName>
								<orgName type="department" key="dep2">Institute of Veterinary Science</orgName>
								<orgName type="institution">University of Liverpool</orgName>
								<address>
									<addrLine>Chester High Road</addrLine>
									<postCode>CH64 7TE</postCode>
									<settlement>Leahurst Campus, Neston</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Equine Clinical Studies</orgName>
								<orgName type="department" key="dep2">Institute of Veterinary Science</orgName>
								<orgName type="institution">University of Liverpool</orgName>
								<address>
									<addrLine>Chester High Road</addrLine>
									<postCode>CH64 7TE</postCode>
									<settlement>Leahurst Campus, Neston</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mandy</forename><forename type="middle">J</forename><surname>Peffers</surname></persName>
							<idno type="ORCID">0000-0001-6028-4154</idno>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Musculoskeletal Biology</orgName>
								<orgName type="department" key="dep2">Institute of Ageing and Chronic Disease</orgName>
								<orgName type="institution">University of Liverpool</orgName>
								<address>
									<settlement>Liverpool</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katie</forename><surname>Lee</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Musculoskeletal Biology</orgName>
								<orgName type="department" key="dep2">Institute of Ageing and Chronic Disease</orgName>
								<orgName type="institution">University of Liverpool</orgName>
								<address>
									<settlement>Liverpool</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luis</forename><forename type="middle">M</forename><surname>Rubio-Martinez</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Equine Clinical Studies</orgName>
								<orgName type="department" key="dep2">Institute of Veterinary Science</orgName>
								<orgName type="institution">University of Liverpool</orgName>
								<address>
									<addrLine>Chester High Road</addrLine>
									<postCode>CH64 7TE</postCode>
									<settlement>Leahurst Campus, Neston</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Equine Clinical Studies</orgName>
								<orgName type="department" key="dep2">Institute of Veterinary Science</orgName>
								<orgName type="institution">University of Liverpool</orgName>
								<address>
									<addrLine>Chester High Road</addrLine>
									<postCode>CH64 7TE</postCode>
									<settlement>Leahurst Campus, Neston</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Effects of stanozolol on normal and IL-1β-stimulated equine chondrocytes in vitro</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">8387645A82A1D20C68BD22BD18A53540</idno>
					<idno type="DOI">10.1186/s12917-018-1426-z</idno>
					<note type="submission">Received: 23 September 2017 Accepted: 14 March 2018</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:18+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Osteoarthritis</term>
					<term>Stanozolol</term>
					<term>Chondrocyte</term>
					<term>Equine</term>
					<term>Gene expression</term>
					<term>In vitro</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Intra-articular administration of stanozolol has shown promising results by improving the clinical management of lameness associated with naturally-occurring osteoarthritis (OA) in horses, and by decreasing osteophyte formation and subchondral bone reaction in sheep following surgically induced OA.</s><s>However, there is limited evidence on the anti-inflammatory and modulatory properties of stanozolol on articular tissues.</s><s>The objective of the current study was to evaluate the effects of stanozolol on chondrocyte viability and gene expression in normal equine chondrocytes and an inflammatory in vitro system of OA (interleukin-1β (IL-1β) treated chondrocytes).</s></p><p><s>Results: Chondrocytes from normal metacarpophalangeal joints of skeletally mature horses were exposed to four treatment groups: (1) media only (2) media+IL-1β (3) media+IL-1β + stanozolol (4) media+stanozolol.</s><s>Following exposure, chondrocyte viability and the expression of catabolic, anabolic and structural genes were determined.</s><s>General linear models with Dunnet's comparisons with Bonferroni's adjustment were performed.</s><s>Cell viability was similar in all groups.</s><s>Stanozolol treatment reduced gene expression of MMP-13, MMP-1, IL-6 and COX-2 in both normal and IL-1β treated chondrocytes.</s><s>Stanozolol treatment reduced ADAMTS4 gene expression in normal chondrocytes.</s><s>Stanozolol reduced the expression of COL2A1.</s><s>Conclusions: The current study demonstrates stanozolol has chondroprotective effects through downregulation of genes for pro-inflammatory/catabolic cytokines and enzymes associated with OA.</s><s>However, there is no evidence of increased cartilage stimulation through upregulation of the anabolic and structural genes tested.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Osteoarthritis (OA) is caused by a combination of biomechanical and biochemical changes in the joint that include synovium and subchondral bone abnormalities, ultimately resulting in cartilage degeneration <ref type="bibr" target="#b0">[1]</ref>.</s><s>In the past decade, major advances have been made in molecular biology and OA research in both human and veterinary medicine.</s><s>Equine models have been used extensively providing invaluable insights into the molecular pathogenesis during disease establishment and in response to treatment <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s></p><p><s>One of the main goals in the treatment of OA is to inhibit further progression of cartilage degeneration and to restore a functional synovial environment with the potential to promote cartilage repair.</s><s>Cartilage repair is mediated by the balance between chondrocyte gene expression of catabolic and anabolic genes <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s>The most important mediator of cartilage degeneration is interleukin-1 (IL-1) <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> and it has been reported that low innate production of IL-1β and IL-6 is associated with the absence of OA in old age <ref type="bibr" target="#b6">[7]</ref>.</s><s>IL-1 enhances the expression of pro-inflammatory mediators including matrix metalloproteinases (MMP-3 and -13), inflammatory cytokines (IL-6), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS-4 and -5), cyclooxygenase 2 (COX-2), prostaglandin E2 (PGE2) and free radicals <ref type="bibr" target="#b0">[1]</ref>.</s><s>Cartilage repair is mediated by anabolic growth factors including the transforming growth factor β (TGF-β), insulin-like growth factor 1 (IGF-1), bone morphogenetic proteins (BMPs) and fibroblast growth factors (FGF) <ref type="bibr" target="#b7">[8]</ref>.</s><s>The IGF-1, TGF-β and BMPs act in part by induction of the transcription factor SOX-9, a key regulator of mesenchymal chondrogenesis during embryologic development <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref>.</s><s>No therapy is currently available to prevent the onset or progression of OA, and latest research has focused on disease-modifying drugs with the capacity not only to counteract the effects of pro-inflammatory cytokines but also to promote articular cartilage repair.</s></p><p><s>Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone and were first introduced in the early 1930s.</s><s>Since then, an attempt has been made to minimize the androgenic side effects by increasing their anabolic: androgenic ratio.</s><s>Stanozolol has one of the highest anabolic: androgenic ratios, suggesting it has anabolic activity with minimal androgenic side effects <ref type="bibr" target="#b10">[11]</ref>.</s><s>Stanozolol has a wide range of applications in human medicine and has been used to treat rheumatoid arthritis <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>, hereditary angioedema <ref type="bibr" target="#b13">[14]</ref>, idiopathic osteonecrosis <ref type="bibr" target="#b14">[15]</ref>, postmenopausal osteoporosis <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17]</ref>, muscle wastage and age-related sarcopenia <ref type="bibr" target="#b10">[11]</ref>, amongst others <ref type="bibr" target="#b17">[18]</ref>.</s><s>The main claims for stanozolol's therapeutic effects are based on its anabolic activity on the musculoskeletal system and its potential to influence lean body mass, tissue repair, fibrinolysis, collagen synthesis and bone metabolism <ref type="bibr" target="#b10">[11]</ref>.</s><s>To our knowledge there are no human studies evaluating the effects of AAS on articular cartilage and there are no reports on the intra-articular use of stanozolol in human patients.</s></p><p><s>Intra-articular administration of stanozolol has recently been postulated as a treatment for OA.</s><s>Studies investigating the clinical effects of the intra-articular use of stanozolol in horses have shown promising results in the ability of this drug to effectively manage lameness associated with OA and have suggested that stanozolol has the potential to stimulate cartilage repair <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>.</s><s>There is also anecdotal evidence of positive results obtained in equine clinical practice, including cases refractory to intra-articular glucocorticoids <ref type="bibr" target="#b20">[21]</ref> and in the management of subchondral bone pain <ref type="bibr" target="#b21">[22]</ref>.</s><s>Furthermore, stanozolol has been used in an experimental animal model (sheep meniscectomy), demonstrating decreased osteophyte formation, subchondral bone reaction and synovial fibrosis, and articular cartilage regeneration <ref type="bibr" target="#b22">[23]</ref>.</s><s>However, there is limited evidence of the antiinflammatory properties of stanozolol and how it affects articular chondrocytes in vitro.</s><s>Previous data suggests that it reduces chondrocyte apoptosis by decreasing the production of nitric oxide in equine chondrocytes <ref type="bibr" target="#b23">[24]</ref>, enhances collagen synthesis though the upregulation of TGF-β in adult human dermal fibroblasts <ref type="bibr" target="#b24">[25]</ref> and enhances the proliferation of cultured growth plate chondrocytes from pubertal female rats treated with GnRHa <ref type="bibr" target="#b25">[26]</ref>.</s></p><p><s>The objective of the current study is to evaluate the effect of stanozolol on chondrocyte viability and gene expression in normal chondrocytes and an in vitro inflammatory system of OA.</s><s>We hypothesise that stanozolol will not have an effect on chondrocyte viability; will have a chondroprotective effect by reducing the expression of pro-inflammatory/catabolic genes (MMP-13, MMP-1, IL-6, ADAMTS4 and COX-2) in both normal and IL-1β treated chondrocytes; and will have an anabolic effect by increasing the expression of SOX9, COL2A1 and aggrecan in both normal and IL-1β treated chondrocytes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample collection</head><p><s>Articular cartilage was aseptically harvested from the entire articular surface of macroscopically normal metacarpophalangeal joints of seven skeletally mature horses euthanized for reasons unrelated to this study, ages ranging from five to eleven years (mean 7.7 +/− SD 2.1).</s><s>Samples were collected from an abattoir as a by-product of the agricultural industry and processed within 12 h of euthanasia.</s><s>The Animals (Scientific Procedures) Act 1986, Schedule 2, does not define collection from these sources as scientific procedures and ethical approval was therefore not required.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tissue culture and cell viability</head><p><s>The chondrocytes were isolated as previously described <ref type="bibr" target="#b26">[27]</ref> and the cell viability was determined by trypan blue exclusion test <ref type="bibr" target="#b27">[28]</ref> for each horse.</s><s>The chondrocytes were then plated as monolayers in Dulbecco's modified eagles medium (DMEM) (Sigma-Aldrich, Dorset, UK), supplemented with 10% foetal calf serum (FCS), 100 units/ml penicillin, 100 mg/ml streptomycin (all from Invitrogen, Paisley, UK) and 500 ng/ml amphotericin B (BioWhittaker, Lonza, USA), at a concentration of 100,000 live cells/cm 2 (total of 16 wells of a 24-well plate used per horse).</s><s>The chondrocytes were incubated in a 5% CO 2 humidified atmosphere at 37 °C for 48 h.</s><s>The medium was changed and replaced with serum-free DMEM 24 h prior to exposure.</s><s>Each horse was exposed to 4 different treatment groups (4 wells per group): (1) media only (negative control) (2) media + IL-1β (Recombinant Equine IL-1β, R&amp;D Systems, Abingdon, UK) (10 ng/ml) (positive control) (3) media + IL-1β (10 ng/ml) + stanozolol (Sungate, ACME, Cavriago, Italy) (0.4 mg/ml) 4) media + stanozolol (0.4 mg/ml).</s><s>The stanozolol concentration was extrapolated by using the clinically recommended dose of 5 mg per joint <ref type="bibr" target="#b19">[20]</ref> and assuming the volume of a non-distended metacarpalphalangeal joint to be 12.5 ml <ref type="bibr" target="#b28">[29]</ref>.</s><s>After 24 h in culture conditions, cell viability was performed on one well per group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Real-time PCR</head><p><s>Total RNA was isolated separately from 3 wells per group using 0.5 ml of Tri Reagent (Sigma-Aldrich, Dorset, UK) per well and stored at -80 °C for later analysis.</s><s>The RNA isolated from each well was processed individually and was purified by the acid guanidinium thiocyanate-phenol-chloroform extraction technique as previously described <ref type="bibr" target="#b29">[30]</ref>.</s><s>Total RNA concentrations and purity were determined spectrophotometrically (NanoDrop™ 1000 Spectrophotometer, Thermo Fisher Scientific, Waltham, US) and all the samples used presented a ratio of absorbance at 260 nm and 280 nm (A 260 /A 280 ) between 1.8 and 2.0.</s><s>cDNA was synthetized from 500 ng of RNA in a 29 μL reaction using Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) and random hexamer oligonucleotides (both Promega, Southampton, UK). cDNA samples were individually diluted to a final concentration of 5 ng/μL and 5 μL aliquots of cDNA were amplified by reverse transcription polymerase chain reaction (RT-PCR) (ABI PRISM® 7500 Sequence Detection System, Applied Biosystems, Warrington, UK) in a 20 μL reaction volume using a SYBR Green PCR mastermix (Applied Biosystems, Warrington, UK).</s><s>Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene and the relative expression of catabolic, anabolic and structural genes was analysed using the 2 -ΔΔC T method <ref type="bibr" target="#b30">[31]</ref>.</s><s>The fitness of GAPDH as a valid normalisation factor has been previously identified by us <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33]</ref>.</s><s>All primers used were designed by Applied Biosystems Assays-by-Design and have been previously validated by our group.</s><s>Primers for equine IL-6 and COX-2 had the following sequences: IL-6 Forward: CTG-CTC-CTG-GTG-ATG-G CT-AC, Reverse: CCG-AGG-ATG-TGT-ACT-TAA-T GT-GCT-G; COX-2 Forward: CAG-CAT-AAA-CTG-C GC-CTT-TTC, Reverse: AGG-CGG-GTA-GAT-CAT-T TC-CA.</s><s>The primer sequences for GAPDH, SOX9, COL2A1, aggrecan, MMP-13 and -1, and ADAMTS4 have been previously reported <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b33">34]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Statistical analysis was performed using SPSS (IBM, Portsmouth, UK).</s><s>Normality of the data was analysed using a Shapiro-Wilk test, and non-parametric data was LOG 10 transformed prior to analysis.</s><s>A general linear model was used for all analyses with Dunnet's comparisons against the control group and pairwise comparisons with Bonferroni's adjustment.</s><s>Statistical significance was defined as P &lt; 0.05.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Stanozolol does not affect chondrocyte viability</head><p><s>There were no significant differences in cell viability between the different treatment groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Stanozolol reduces catabolic gene expression</head><p><s>There was a statistically significant increase in the expression of MMP-13, MMP-1, IL-6, ADAMTS4 and COX-2 mRNA expression in chondrocytes treated with IL-1β only (group 2-positive control) compared to media only (group 1-negative control) (P &lt; 0.001).</s><s>Conversely, chondrocytes exposed to stanozolol only (group 4) had a significantly decreased expression of all the above catabolic genes compared to the negative control (group 1) (P &lt; 0.001) (Fig. <ref type="figure" target="#fig_0">1</ref>).</s></p><p><s>When comparing both groups with IL-1β treated chondrocytes, there was a significant downregulation of MMP-13 (P &lt; 0.001), MMP-1 (P &lt; 0.03), IL-6 (P &lt; 0.001) and COX-2 (P &lt; 0.001) expression in chondrocytes exposed to IL-1β and stanozolol (group 3) compared to chondrocytes exposed to IL-1β alone (group 2).</s><s>ADAMTS4 gene expression was not significantly supressed in chondrocytes exposed to IL-1β and stanozolol (group 3) compared to chondrocytes exposed to IL-1β only (group 2) (Fig. <ref type="figure" target="#fig_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Stanazolol reduces COL2A1 gene expression</head><p><s>There was no statistically significant difference in SOX9 gene expression between treatment groups.</s><s>COL2A1 gene expression was significantly supressed in both groups treated with stanozolol (groups 3 and 4) compared to both groups not treated with stanozolol (groups 1 and 2).</s><s>Aggrecan gene expression was significantly supressed in both groups treated with IL-1β (groups 2 and 3) compared to both groups not treated with IL-1β (groups 1 and 4).</s><s>No statistically significant difference was seen on COL2A1 gene expression between groups 1 and 2 or 3 and 4, or on aggrecan expression between groups 1 and 4 or 2 and 3 (Fig. <ref type="figure" target="#fig_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In OA the balance between anabolic and catabolic activities is compromised and cartilage degeneration prevails over the capacity of repair.</s><s>In the present study, treatment with stanozolol was investigated in both normal and IL-1β stimulated chondrocytes.</s><s>In accordance with previous reports <ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref> exposure to IL-1β induced a catabolic response on equine articular chondrocytes and increased the gene expression of MMP-13, MMP-1, IL-6, ADAMTS4 and COX-2.</s><s>Addition of stanozolol to IL-1β stimulated chondrocytes counteracted the catabolic effects of IL-1β and downregulated the expression of MMP-13, MMP-1, IL-6, and COX-2.</s><s>Similarly, corticosteroids have been demonstrated to inhibit MMP transcription <ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref> and downregulate the expression of COX-2 <ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref> in cytokine-treated chondrocytes.</s><s>In the present study, stanozolol supressed ADAMTS4 gene expression in normal chondrocytes compared to control but did not counteract the upregulation induced by IL-1β.</s><s>This is in contrast with observations in corticosteroids studies <ref type="bibr" target="#b38">[39,</ref><ref type="bibr" target="#b39">40]</ref>.</s></p><p><s>Further analysis of our results showed that when normal chondrocytes were treated with stanozolol there was a significant decrease in the expression of all the catabolic genes tested (MMP-13, MMP-1, IL-6, ADAMTS4 and COX-2) compared to control.</s><s>Again, similar results have been obtained in in vitro models studying the effects of corticosteroids on articular cartilage <ref type="bibr" target="#b37">[38,</ref><ref type="bibr" target="#b38">39]</ref>.</s><s>Knych et al. <ref type="bibr" target="#b42">[43]</ref> recently evaluated changes in synovial fluid gene expression following in vivo administration of triamcinolone in healthy horses undergoing a standardized exercise programme.</s><s>In this study they found no significant differences in COX-2 and MMP-3 gene expression between baseline and the triamcinolone treatment group.</s><s>These results suggest a protective and stronger anti-inflammatory response after intra-articular administration of stanozolol compared to triamcinolone; however, different experimental models limit direct comparisons between studies.</s></p><p><s>Contrary to our hypothesis, stanozolol did not enhance the expression of SOX-9, COL2A1 or aggrecan.</s><s>The pathway through which anabolic growth factors promote upregulation of chondrocyte specific genes remains largely unclear.</s><s>The transcription factor SOX9 has elicited much interest as it is co-expressed with type II collagen in mouse fetal chondrocytes and is thought to be involved in chondrocyte differentiation and cartilage formation during development <ref type="bibr" target="#b43">[44]</ref>.</s><s>SOX9 has been shown to mediate the expression of many genes encoding cartilage extracellular matrix proteins, including COL2A1 and aggrecan <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b45">46]</ref>.</s><s>Kolettas et al. <ref type="bibr" target="#b8">[9]</ref> investigated the effects of IGF-1 and IL-1 on chondrocyte survival and phenotype and reported an antagonist effect.</s><s>IL-1 supressed the expression of chondrocyte-specific genes (collagen types II and IX, aggrecan, biglycan and link protein) and downregulated SOX-9; and IGF-1 upregulated SOX-9, relieved the IL-1 induced inhibition of chondrocyte-specific genes and enhanced chondrocyte survival.</s><s>The authors therefore suggested that IGF-1 and IL-1 modulate chondrocyte survival and differentiation through changes in SOX-9 gene expression.</s><s>Further studies have challenged this concept and showed a negative correlation between COL2A1 and SOX9 gene expression.</s><s>In human adult articular chondrocytes, IL-1 had no significant influence on SOX9 mRNA expression whereas COL2A1 was significantly down- Real-time-PCR analysis of the above genes mRNA in monolayer cultures exposed to media, IL-1β, IL-1β + stanozolol and stanozolol.</s><s>GAPDH was used as the housekeeping gene and data are represented as relative expression using the 2 -ΔΔC T method.</s><s>Data were evaluated using a general linear model with Dunnet's comparisons against the control group and pairwise comparisons with Bonferroni's adjustment (n = 7, three technical replicates per treatment group) regulated.</s><s>The same experiment also demonstrated that IGF-I up-regulated COL2A1 expression, but not SOX9 <ref type="bibr" target="#b46">[47]</ref>.</s><s>In our study, treatment with IL-1 and stanozolol, alone or in combination, did not alter SOX-9 gene expression in comparison to control.</s><s>IL-1 did not downregulate SOX-9 as previously reported, had no effect on COL2A1 and downregulated aggrecan expression.</s><s>Furthermore, treatment with stanozolol supressed COL2A1 without affecting SOX-9 gene expression.</s><s>Our results suggest that COL2A1 and aggrecan gene expression are not correlated with the expression of SOX9 in equine articular chondrocytes and that treatment with stanozolol does not elicit an anabolic response through the upregulation of SOX-9, COL2A1 or aggrecan.</s></p><p><s>Both COL2A1 and aggrecan are important structural genes essential for cartilage integrity and formation.</s><s>Stanozolol has been shown to increase collagen synthesis in cultures of human dermal fibroblasts <ref type="bibr" target="#b24">[25]</ref>.</s><s>The decrease in COL2A1 levels, which we have observed when chondrocytes were treated with stanozolol, goes against what has been reported in human dermal fibroblasts, and is similar to that reported by Knych et al. <ref type="bibr" target="#b42">[43]</ref> in synovial fluid and Richardson and Dodge <ref type="bibr" target="#b37">[38]</ref> in articular chondrocytes following treatment with corticosteroids.</s><s>In the present study, aggrecan expression was downregulated by IL-1β and treatment with stanozolol did not ameliorate the IL-1 inhibition of aggrecan, which is also in accordance with what has been reported with corticosteroids <ref type="bibr" target="#b37">[38]</ref>.</s><s>Furthermore, the downregulation of COL2A1 induced by stanozolol in this study warrants careful consideration of its intra-articular use as it may suggest deleterious effects on cartilage.</s><s>A limitation of our study is the use of a short-term in vitro system and different results may have been obtained with longer exposure times or with repeat exposures mimicking what has been described in clinical trials.</s><s>Additionally, this study used chondrocytes and not cartilage explants.</s><s>However, we used freshly isolated chondrocytes plated at high density in order to reduce dedifferentiation of chondrocytes in cell culture which can results in an altered phenotype.</s><s>Future studies using cartilage explants are needed.</s></p><p><s>The similarities between the anti-catabolic effects of stanozolol and corticosteroids might be associated with the previously reported affinity of AAS for the glucocorticoid receptors <ref type="bibr" target="#b47">[48]</ref>.</s><s>Alternative pathways through which AAS might be able to exert an anabolic effect on articular tissues merit further investigation; and a plausible explanation for the lack of anabolic activity in our in vitro system might be related to a single and short-lived exposure time.</s><s>Further studies investigating the systemic effects of a low intra-articular dose of stanozolol and its local effects on articular tissues with naturally-occurring OA are warranted.</s><s>The use of AAS is banned by the main organizations overseeing drug regulation in sport, therefore its use should only be considered in noncompeting individuals.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Stanozolol has been described as having disease-modifying activity by attenuating the degenerative response in osteoarthritic cartilage in in vivo studies.</s><s>The results of our in vitro study support the hypothesis that stanozolol has an anti-inflammatory effect and is effective at inhibiting the production of pro-inflammatory mediators in both normal and IL-1 treated chondrocytes.</s><s>However, in our in vitro system there is no evidence of stanozolol having an anabolic effect through upregulation of SOX-9, COL2A1 and aggrecan gene expression.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 Effects of stanozolol on (a) ADAMTS4, (b) IL-6, (c) COX-2, (d) MMP-13 and (e) MMP-1 gene expression in normal and IL-1β-treated equine articular chondrocytes.</s><s>Real-time-PCR analysis of the above genes mRNA in monolayer cultures exposed to media, IL-1β, IL-1β + stanozolol and stanozolol.</s><s>GAPDH was used as the housekeeping gene and data are represented as relative expression using the 2 -ΔΔC T method.</s><s>Data were evaluated using a general linear model with Dunnet's comparisons against the control group and pairwise comparisons with Bonferroni's adjustment (n = 7, three technical replicates per treatment group)</s></p></div></figDesc><graphic coords="4,156.34,112.04,160.12,415.12" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc><div><p><s>Fig. 2 Effect of stanozolol on (a) COL2A1, (b) SOX-9 and (c) aggrecan gene expression in normal and IL-1β-treated equine articular chondrocytes.Real-time-PCR analysis of the above genes mRNA in monolayer cultures exposed to media, IL-1β, IL-1β + stanozolol and stanozolol.</s><s>GAPDH was used as the housekeeping gene and data are represented as relative expression using the 2 -ΔΔC</s></p></div></figDesc></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The authors would like to thank Maria M. Torres for her assistance in the acquisition of data.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Availability of data and materials</head><p><s>Raw data (Excel file) is available from the corresponding author upon request.</s></p><p><s>Authors' contributions MCM, LRM and MJP were involved in the conception, design of the study and experiments, and the analysis and interpretation of data.</s><s>MCM was involved in organizing this research, the acquisition of data and drafting the manuscript.</s><s>KL was involved in the statistical analysis and interpretation of data.</s><s>All authors read and approved the final manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval and consent to participate</head><p><s>Tissue samples from deceased horses euthanized for reasons unrelated to this study were collected from an abattoir as a by-product of the agricultural industry.</s><s>The Animals (Scientific Procedures) Act 1986, Schedule 2, does not define collection from these sources as scientific procedures and ethical approval was therefore not required.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent for publication</head><p><s>Not applicable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>The authors declare that they have no competing interests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publisher's Note</head><p><s>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Traumatic arthritis and posttraumatic osteoarthritis in the horse</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Mcilwraith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Joint disease in the horse</title>
				<editor>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Mi</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Frisbie</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">C</forename><surname>Kawcak</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">R</forename><surname>Van Weeren</surname></persName>
		</editor>
		<meeting><address><addrLine>Missouri</addrLine></address></meeting>
		<imprint>
			<publisher>Elsevier</publisher>
			<date type="published" when="2016">2016</date>
			<biblScope unit="page" from="33" to="48" />
		</imprint>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Animal models of osteoarthritis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Little</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cur Rheumatol Rev</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="175" to="182" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The horse as a model of naturally occurring osteoarthritis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Mcilwraith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Frisbie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Kawcak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Joint Res</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="297" to="309" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Goldring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Otero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tsuchimochi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="75" to="82" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Anabolic/catabolic balance in pathogenesis of osteoarthritis: identifying molecular targets</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Mueller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Tuan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PM&amp;R</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="S3" to="11" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Cytokine targeting in osteoarthritis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Blom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Van Der Kraan</surname></persName>
		</author>
		<author>
			<persName><surname>Van Den</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Berg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Drug Targets</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="283" to="292" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Low innate production of interleukin-1β and interleukin-6 is associated with the absence of osteoarthritis in old age</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Goekoop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kloppenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kroon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoarthr Cartil</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="942" to="947" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The role of growth factors in cartilage repair</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Fortier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">U</forename><surname>Barker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Strauss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Orthop Relat Res</title>
		<imprint>
			<biblScope unit="volume">469</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2706" to="2715" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Chondrocyte phenotype and cell survival are regulated by culture conditions and by specific cytokines through the expression of sox-9 transcription factor</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kolettas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Muir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hardingham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1146" to="1156" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9</title>
		<author>
			<persName><forename type="first">T</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wirth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Meyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1111" to="1120" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Current concepts in anabolic-androgenic steroids</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Evans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Sports Med</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="534" to="542" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Belch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Madhok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mcardle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Q J Med</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="19" to="27" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Disease modifying drugs for rheumatoid arthritis: yesterday&apos;s treatment today or today&apos;s treatment tomorrow?</title>
		<author>
			<persName><forename type="first">T</forename><surname>Pullar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="501" to="510" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Hereditary angioedema: safety of long-term stanozolol therapy</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Sloane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Sheffer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="654" to="658" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein (a), and therapy with Stanozolol</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Glueck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Freiberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Glueck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="213" to="220" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Chesnut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Ivey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Gruber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Metabolism</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="571" to="580" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Osteoporosis and its treatments</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>El-Ganzuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Bastawy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J Adv Res</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="303" to="318" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Stanozolol as a novel therapeutic agent in dermatology</title>
		<author>
			<persName><forename type="first">T</forename><surname>Helfman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Falanga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="254" to="258" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Clinical evaluation of intraarticular administration of stanozolol to manage lameness associated with acute and chronic osteoarthritis in horses</title>
		<author>
			<persName><forename type="first">A</forename><surname>Spadari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rinnovati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Babbini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Romagnoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Equine Vet Sci</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="105" to="110" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Dose-finding study for intraarticular treatment with Stanozolol in horses</title>
		<author>
			<persName><forename type="first">R</forename><surname>Rinnovati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Romagnoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Spadari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Equine Vet Sci</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="860" to="864" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Preliminary clinical impressions on the use of stanozolol as a novel intra-articular therapy for athletic horses: 60 cases (abstract)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ramzan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Somerville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shepherd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Users/mcm/Downloads/CH08-Ramzan-PreliminaryClinical%20(1).pdf. Accessed</title>
				<imprint>
			<date type="published" when="2012-04-04">2012. 4 Apr 2012</date>
		</imprint>
	</monogr>
	<note>In: Abstracts European veterinary conference Voorjaarsdagen</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">Managing subchondral bone pain in thoroughbreds</title>
		<author>
			<persName><forename type="first">B</forename><surname>Bladon</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
			<publisher>Beva Congress Proceedings</publisher>
			<biblScope unit="page">170</biblScope>
			<pubPlace>Birmingham</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Effects of intraarticular treatment with stanozolol on synovial membrane and cartilage in an ovine model of osteoarthritis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Spadari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Romagnoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Predieri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Res Vet Sci</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="379" to="387" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Stanozolol inhibits nitric oxide production by horse chondrocyte cell cultures (abstract)</title>
		<author>
			<persName><forename type="first">R</forename><surname>Saleri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dondi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bianchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="S38" to="39" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>Abstracts from the workshop: Frontiers of skeletal biology</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Stimulation of collagen synthesis by the anabolic steroid stanozolol</title>
		<author>
			<persName><forename type="first">V</forename><surname>Falanga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Greenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1193" to="1197" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Effects of Stanozolol on proliferation and differentiation of cultured growth plate chondrocytes from pubertal female rat treated with GnRHa in vitro</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">H</forename><surname>Shun-Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hua-Mei</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yan-Hong</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Sun Yat-Sen Univ (Med Sci)</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">18</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Cellular methods in cartilage research: primary human chondrocytes in culture and chondrogenesis in human bone marrow stem cells</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Tew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Murdoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Rauchenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hardingham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Methods</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="2" to="9" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Trypan blue exclusion test of cell viability</title>
		<author>
			<persName><forename type="first">W</forename><surname>Strober</surname></persName>
		</author>
		<idno type="DOI">10.1002/0471142735.ima03bs21</idno>
		<ptr target="http://dx.doi.org/10.1002/0471142735.ima03bs21" />
	</analytic>
	<monogr>
		<title level="j">Curr Protoc Immunol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Volume of the synovia in certain joint cavities in the horse</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ekman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Persson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lumsdan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Vet Scand (Denmark)</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="23" to="31" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on</title>
		<author>
			<persName><forename type="first">P</forename><surname>Chomczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sacchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="581" to="585" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Analysis of relative gene expression data using realtime quantitative PCR and the 2− ΔΔCT method</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Livak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Schmittgen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Methods</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="402" to="408" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Regulation of SOX9 in normal and osteoarthritic equine articular chondrocytes by hyperosmotic loading</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Peffers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">I</forename><surname>Milner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Tew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Clegg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoarthr Cartil</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1502" to="1508" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Hyperosmolarity regulates SOX9 mRNA posttranscriptionally in human articular chondrocytes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Tew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Peffers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Mckay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Lowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hardingham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Clegg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Cell Physiol</title>
		<imprint>
			<biblScope unit="volume">297</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="C898" to="906" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Transcriptomic signatures in cartilage ageing</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Peffers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Clegg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">R98</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Effects of interleukin-1β and tumor necrosis factor-α on expression of matrix-related genes by cultured equine articular chondrocytes</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Dodge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Vet Res</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="624" to="630" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Recombinant equine interleukin-1ß induces putative mediators of articular cartilage degradation in equine chondrocytes</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Tung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Fenton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Arnold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Vet Res</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="19" to="25" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Evaluation of the inflammatory response in experimentally induced synovitis in the horse: a comparison of recombinant equine interleukin 1 beta and lipopolysaccharide</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Kisiday</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Mcilwraith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoarthr Cartil</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1583" to="1590" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Dose-dependent effects of corticosteroids on the expression of matrix-related genes in normal and cytokine-treated articular chondrocytes</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Dodge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Inflamm Res</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="39" to="49" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Effects of glucocorticoids and interleukin-1β on expression and activity of aggrecanases in equine chondrocytes</title>
		<author>
			<persName><forename type="first">E</forename><surname>Busschers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Holt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Richardson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Vet Res</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="176" to="185" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Influence of corticosteroids on interleukin-1β-stimulated equine chondrocyte gene expression</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Caron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Gandy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vet Surg</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="231" to="237" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Effects of sodium hyaluronate and triamcinolone acetonide on glucosaminoglycan metabolism in equine articular chondrocytes treated with interleukin-1</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Schaefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Durgam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Vet Res</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1494" to="1501" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Effects of sodium hyaluronate and methylprednisolone acetate on proteoglycan metabolism in equine articular chondrocytes treated with interleukin-1</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Yates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Byron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Vet Res</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1980" to="1986" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Cytokine, catabolic enzyme and structural matrix gene expression in synovial fluid following intraarticular administration of triamcinolone acetonide in exercised horses</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Knych</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Vidal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chouicha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Equine Vet J</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="107" to="115" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">SOX9 binds DNA, activates transcription, and coexpresses with type II collagen during chondrogenesis in the mouse</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wheatley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Muscat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dev Biol</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="108" to="121" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">SOX9 directly regulates the type 2 collagen gene</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Bell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Wheatley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="174" to="178" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Sox9 is required for cartilage formation</title>
		<author>
			<persName><forename type="first">W</forename><surname>Bi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Behringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>De Crombrugghe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="85" to="89" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">SOX9 expression does not correlate with type II collagen expression in adult articular chondrocytes</title>
		<author>
			<persName><forename type="first">T</forename><surname>Aigner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Gebhard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Schmid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Matrix Biol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="363" to="372" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Anabolic-androgenic steroid therapy in the treatment of chronic diseases</title>
		<author>
			<persName><forename type="first">S</forename><surname>Basaria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wahlstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Dobs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="5108" to="5117" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
